Circuit Therapeutics Announces Research Collaboration with Lundbeck

Posted December 2016

Menlo Park, CA, 19 December 2016 - Circuit Therapeutics today announced a research collaboration with Lundbeck, a global pharmaceutical company specializing in psychiatric and neurological disorders, using Circuit’s proprietary optogenetics technology platform. This new collaboration has the aim of extending the knowledge around neural circuits associated with psychiatric symptoms and the development of novel medicines to treat those symptoms.

“We are excited to add Lundbeck to our research partnerships, allowing Circuit’s unique technical capacities to continue to contribute to finding new ways to solve the difficult problems inherent in psychiatric disorder treatment. We aim to mesh Lundbeck’s focus and our optogenetic approach with the goal of positively impacting patients suffering from psychiatric disorders,” said Fred Moll, CEO and Chairman of Circuit Therapeutics.

About Circuit Therapeutics

Circuit Therapeutics Circuit Therapeutics is the world leader in optogenetics – a transformational technology that gives researchers and clinicians the ability to control neural activity with light. Optogenetics enables unparalleled specificity and temporal control of neural circuits, and has allowed Circuit to create an unrivaled platform for discovery and validation of novel drug targets. Founded by Karl Deisseroth, Rob Malenka, Scott Delp, Thomas Sudhof, and Karoly Nikolich, Circuit Therapeutics is based in Menlo Park, California.

For more information, please visit www.circuittx.com, or contact Dana Carnes, dcarnes@circuittx.com

Circuit Therapeutics contact

Circuit Therapeutics, Inc.
Media: Dana Carnes, Director of Operations
(650) 543-1441
dcarnes@circuittx.com